New PIN1 inhibitors identified through a pharmacophore-driven, hierarchical consensus docking strategy

Abstract PIN1 is considered as a therapeutic target for a wide variety of tumours. However, most of known inhibitors are devoid of cellular activity despite their good enzyme inhibitory profile. Hence, the lack of effective compounds for the clinic makes the identification of novel PIN1 inhibitors a hot topic in the medicinal chemistry field. In this work, we reported a virtual screening study for the identification of new promising PIN1 inhibitors. A receptor-based procedure was applied to screen different chemical databases of commercial compounds. Based on the whole workflow, two compounds were selected and biologically evaluated. Both ligands, compounds VS1 and VS2, showed a good enzyme inhibitory activity and VS2 also demonstrated a promising antitumoral activity in ovarian cancer cells. These results confirmed the reliability of our in silico protocol and provided a structurally novel ligand as a valuable starting point for the development of new PIN1 inhibitors.

[1]  Colin J. Daniel,et al.  Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo , 2021, Nature Chemical Biology.

[2]  Flavio Rizzolio,et al.  Virtual screening identifies a PIN1 inhibitor with possible antiovarian cancer effects , 2019, Journal of cellular physiology.

[3]  A. Giordano,et al.  A Guide to PIN1 Function and Mutations Across Cancers , 2019, Front. Pharmacol..

[4]  Shiming Yang,et al.  Prolyl isomerase Pin1: a promoter of cancer and a target for therapy , 2018, Cell Death & Disease.

[5]  V. Canzonieri,et al.  Liposomal delivery of a Pin1 inhibitor complexed with cyclodextrins as new therapy for high‐grade serous ovarian cancer , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[6]  L. Chiarelli,et al.  New Chromane-Based Derivatives as Inhibitors of Mycobacterium tuberculosis Salicylate Synthase (MbtI): Preliminary Biological Evaluation and Molecular Modeling Studies , 2018, Molecules.

[7]  Thierry Langer,et al.  Conformational Sampling of Small Molecules With iCon: Performance Assessment in Comparison With OMEGA , 2018, Front. Chem..

[8]  M. Longhi,et al.  Artificial Lipid Membrane Permeability Method for Predicting Intestinal Drug Transport: Probing the Determining Step in the Oral Absorption of Sulfadiazine; Influence of the Formation of Binary and Ternary Complexes with Cyclodextrins , 2018, AAPS PharmSciTech.

[9]  A. Rosato,et al.  A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action , 2017, Nature Communications.

[10]  E. Agostoni,et al.  PIN1 Modulates Huntingtin Levels and Aggregate Accumulation: An In vitro Model , 2017, Front. Cell. Neurosci..

[11]  Tiziano Tuccinardi,et al.  Reliability analysis and optimization of the consensus docking approach for the development of virtual screening studies , 2016, Journal of enzyme inhibition and medicinal chemistry.

[12]  Xiao Zhen Zhou,et al.  The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target , 2016, Nature Reviews Cancer.

[13]  T. Hunter,et al.  Prolyl isomerase Pin1 in cancer , 2014, Cell Research.

[14]  A. Giordano,et al.  Pin1 and Nuclear Receptors: A New Language? , 2013, Journal of cellular physiology.

[15]  A. Giordano,et al.  The Prolyl Isomerase Pin1 Acts Synergistically with CDK2 to Regulate the Basal Activity of Estrogen Receptor α in Breast Cancer , 2013, PloS one.

[16]  A. Giordano,et al.  Dissecting Pin1 and phospho‐pRb regulation , 2013, Journal of cellular physiology.

[17]  A. Giordano,et al.  Androgen receptor serine 81 mediates Pin1 interaction and activity , 2012, Cell cycle.

[18]  A. Klein-Szanto,et al.  Retinoblastoma tumor-suppressor protein phosphorylation and inactivation depend on direct interaction with Pin1 , 2012, Cell Death and Differentiation.

[19]  B. Davis,et al.  Discovery of cell-active phenyl-imidazole Pin1 inhibitors by structure-guided fragment evolution. , 2011, Bioorganic & medicinal chemistry letters.

[20]  B. Davis,et al.  Structure-guided design of alpha-amino acid-derived Pin1 inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[21]  Samantha Greasley,et al.  Structure-based design of novel human Pin1 inhibitors (I). , 2009, Bioorganic & medicinal chemistry letters.

[22]  F. Etzkorn Pin1 flips Alzheimer's switch. , 2006, ACS chemical biology.

[23]  Toshiki Nakai,et al.  Prolyl-isomerase Pin1 Accumulates in Lewy Bodies of Parkinson Disease and Facilitates Formation of α-Synuclein Inclusions* , 2006, Journal of Biological Chemistry.

[24]  Priti Garg,et al.  Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis , 2004, The EMBO journal.

[25]  J. Sowadski,et al.  Prevalent overexpression of prolyl isomerase Pin1 in human cancers. , 2004, The American journal of pathology.

[26]  Kristina Luthman,et al.  Caco-2 monolayers in experimental and theoretical predictions of drug transport1PII of original article: S0169-409X(96)00415-2. The article was originally published in Advanced Drug Delivery Reviews 22 (1996) 67–84.1 , 2001 .

[27]  Xiao Zhen Zhou,et al.  Function of WW domains as phosphoserine- or phosphothreonine-binding modules. , 1999, Science.

[28]  G. Fischer,et al.  Selective inactivation of parvulin-like peptidyl-prolyl cis/trans isomerases by juglone. , 1998, Biochemistry.

[29]  George W. A. Milne,et al.  Graph Theory and Group Contributions in the Estimation of Boiling Points , 1994, J. Chem. Inf. Comput. Sci..

[30]  Arup K. Ghose,et al.  Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics , 1989, J. Chem. Inf. Comput. Sci..

[31]  Thierry Langer,et al.  LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..